Industry Satellite Symposia webcasts

26 Jun 2024

AiCME (supported by Bayer)
Navigating New Frontiers: Real World Evidence's Trial in Advancing Later-Line GI Cancer Therapy

Watch session

• Do different sources of data matter? Comparing real-world evidence and clinical trial findings
  Luís Castelo-Branco and Richard D. Kim
• Evaluating RWE in GI cancers: Later-line evidence for TKIs (part 1)
  Richard D. Kim
• Evaluating RWE in GI cancers: Later-line evidence for TKIs (part 2)
  Gerald Prager
• Patient selection in the real world: The correct TKI for the correct patient
  Luís Castelo-Branco, Richard D. Kim and Gerald Prager
• Applying RWE to clinical practice: How does it inform later-line therapy for GI cancers?
  Luís Castelo-Branco and Richard D. Kim
• Conclusion: Audience Q&A and closing remarks
  Luís Castelo-Branco, Richard D. Kim and Gerald Prager

Eisai
Treatment Goals, Clinical Endpoints, RCTs and RWEs: Navigating the Complex Decision Making in First-Line HCC 

Coming soon

• Complexity of first-line treatment approaches for uHCC
  Markus Peck Radosavljevic
• Exploring treatment goals and the value of different clinical endpoints
  Edoardo Giannini
• Evidence-based strategies for managing heterogeneous HCC patient populations in clinical practice
  David J. Pinato
• Debate and Q&A
  Markus Peck Radosavljevic, Edoardo Giannini and David J. Pinato

27 Jun 2024

Astellas
Lighting the Path Ahead: The Future of Precision Medicine in Gastric and Gastro-oesophageal Junction Adenocarcinoma

Watch session

• Welcome and introduction
  Salah-Eddin Al-Batran
• Is light breaking through? The future for the management of G/GEJ adenocarcinoma
  Salah-Eddin Al-Batran
• Seeing the light: Considerations for introducing new therapies into our practice
  Nicola Fazio and Carolina Martinez Ciarpaglini
• When the lights go out: All questions that keep you up at night
  Salah-Eddin Al-Batran, Nicola Fazio and Carolina Martinez Ciarpaglini
• Summary and close
  Salah-Eddin Al-Batran

PeerVoice
Providing Cutting-Edge Care for Cholangiocarcinoma: Transforming the Patient Journey 

Watch session

• Welcome and introduction
  David Malka
• Appreciating the patient experience with cholangiocarcinoma
  Elisabeth Baucells
• Patient-centred care for cholangiocarcinoma at each step of their journey
  David Malka, Anna Saborowski and Elisabeth Baucells
• Discussion and take-home messages
  David Malka, Anna Saborowski and Elisabeth Baucells

Servier
Perspectives on the current and future management of mCRC: Consensus and controversies

Watch session

• Introduction
  Julien Taieb
• New perspectives in the 1st and 2nd line treatment landscape of mCRC
  Jenny Seligmann
• Panel discussion
  Julien Taieb, Sara Lonardi, Jenny Seligmann and Dominik P. Modest
• Optimising treatment options in 3rd line and beyond
  Dominik P. Modest
• Panel discussion
  Julien Taieb, Sara Lonardi, Jenny Seligmann and Dominik P. Modest
• Conclusion
  Sara Lonardi

28 Jun 2024

BeiGene
Advances in Upper GI Immunotherapy: What’s New on the Horizon?

Watch session

• Welcome and introduction
  Sylvie Lorenzen
• Oesophageal squamous cell carcinoma: Treatment landscape, clinical guidelines and immunotherapy
  Filippo Pietrantonio
• A focus on recent data for PD-1 inhibitors in first- and second-line treatment of oesophageal squamous cell carcinoma
  Jean-Philippe Metges
• New era for pathologists: PD-L1 expression in upper GI cancers
  Matteo Fassan
• Management and individualised approaches for patients with gastric and gastro-oesophageal junction adenocarcinoma
  Sylvie Lorenzen
• Novel immunological combinations in first-line treatment of gastric and gastro-oesophageal junction adenocarcinoma
  Maria Alsina Maqueda
• Conclusions and Q&A
  Maria Alsina Maqueda

Bristol Myers Squibb
Evolving Clinical Landscape in GI Cancer: Immuno-oncology and Novel Therapies

Watch session

• Welcome and introduction
  Ian Chau
• Current immune-oncology strategies in gastroesophageal cancers
  Ian Chau
• Advances in the treatment of MSI-H/dMMR and KRAS G12C mutated mCRC
  Sebastian Stintzing
• Updates in immuno-oncology for the treatment of advanced HCC
  Matthias Pinter
• Q&A, summary, and meeting closure
  Ian Chau, Sebastian Stintzing and Matthias Pinter

Daiichi Sankyo
Optimizing the Treatment Continuum with a Molecular-Based Approach in HER2+ GI Cancers

Watch session

• Welcome and introduction
  Josep Tabernero
• Optimizing molecular approaches in HER2+ GI cancers
  Josep Tabernero
• How a biomarker-driven approach is needed across lines of therapy in HER2+ Gastric/GEJ Cancer
  Sara Lonardi
• Exploring new opportunities to improve outcomes in patients with HER2+ mCRC
  Zev A. Wainberg
• The Evolution of HER2 positivity in the treatment of biliary tract cancers
  Zev A. Wainberg
• Safety considerations of HER2-directed therapy in GI cancers
  Sara Lonardi
• Our message worth sharing
  Josep Tabernero, Sara Lonardi and Zev A. Wainberg

Servier
Pathways to Enhance Patients' Benefits in Metastatic Pancreatic Cancer 

Watch session

• Introduction
  Thomas Seufferlein
• New horizons for metastatic pancreatic cancer patients
  Angela Lamarca
• Recent advancements in the treatment of mPAC, focus on Japanese experience
  Akihiro Ohba
• From evidence to clinical practice
  Davide Melisi
• Panel discussion
  Thomas Seufferlein, Angela Lamarca, Akihiro Ohba, Davide Melisi and Radka Obermannova
• Conclusion
  Thomas Seufferlein